Non-animal-based hyaluronic acid fillers: scientific and technical considerations.

Abstract

Recent advances in the technology and biocompatibility of the hyaluronans in all skin types mean that they are becoming the temporary facial filling agents of choice for many aesthetic physicians and surgeons. The hyaluronan products that have been approved for clinical usage by the U.S. Food and Drug Administration and Health Canada were reviewed with respect to their composition, clinical effects and safety profiles, and potential complications. The currently approved accepted standard for the hyaluronan family of fillers of nonanimal bacterial origin includes Restylane and Perlane in the United States and Perlane, Restylane Touch, and SubQ in Canada. Also of nonanimal origin, Juvéderm 24HV, 30, and 30HV were approved by the Food and Drug Administration in June of 2006. Another bacteria-derived hyaluronan filler is Captique; the Hylaform group of hyaluronan fillers is of animal origin and appears to be similar in effect and longevity to Captique. The remarkable biocompatibility of the hyaluronan group of agents in individuals of all skin types, allied with the superior aesthetic result and outstanding longevity of response, promises that patients will continue to demand safe these recent advances in filler technology.